drugset / Trial / NCT02609230
A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will determine the maximum tolerated dose (MTD) and/or the recommended phase II dose (RP2D) of single agent ONC201 in patients with advanced solid tumors or multiple myeloma.
Timeline
- Start
- 2015-11-05
- Primary completion
- 2020-03
- Completion
- 2020-03-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dordaviprone | Small molecule | 125 mg | — |
| Subject | Dordaviprone | Small molecule | 250 mg | — |
| Subject | Dordaviprone | Small molecule | 375 mg | — |
| Subject | Dordaviprone | Small molecule | 500 mg | — |
| Subject | Dordaviprone | Small molecule | 625 mg | — |